Overview

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2027-01-15
Target enrollment:
Participant gender:
Summary
A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
Phase:
Early Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Yake Biotechnology Ltd.